DDInter5 DDInter875
Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1).[L20504,L42715] Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it is a homodimer of two homologous polypeptide chains of 357 amino acids each. It is produced through recombinant DNA technology in mammalian CHO cells. The drug has activity as a selective co-stimulation modulator with inhibitory activity on T lymphocytes. Although approved for the treatment of rheumatoid arthritis, Repligen has entered a slightly different formulation of CTLA4-Ig into clinical trials (RG2077).
Human papillomavirus type 11 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection. It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae* and self-assembled into VLPs.
Abatacept {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Abatacept {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Abatacept {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Omacetaxine mepesuccinate
Abatacept {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alemtuzumab
Abatacept {u} may lead to a major life threatening interaction when taken with {v} Certolizumab pegol
Abatacept {u} may lead to a major life threatening interaction when taken with {v} Natalizumab
Abatacept may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Abatacept may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Abatacept may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Abatacept may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab
Abatacept may lead to a major life threatening interaction when taken with Certolizumab pegol
Abatacept may lead to a major life threatening interaction when taken with Natalizumab